TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of radiation retinopathy.~2. Patients must be 18 years of age or older to receive treatment.~3. Visual acuity of 20/30 to 20/320 in study eye on the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart~4. Visual acuity of 20/800 or better in fellow eye on the ETDRS visual acuity chart.~Exclusion Criteria:~1. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.~2. Patients who have undergone intraocular surgery within the last 2 months~3. Patient participating in any other investigational drug study.~4. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.~5. Inability to obtain photographs to document choroidal neovascularization (CNV) (including difficulty with venous access)~6. Patient with significant liver disease or uremia.~7. Patient with known adverse reaction to fluorescein and indocyanine green or iodine.~8. Patient has a history of any medical condition which would preclude scheduled visits or completion of study~9. Patient has had insertion of scleral buckle in the study eye~10. Patient has received radiation treatment~11. Patient is on anticoagulant therapy with the exception of aspirin~12. Patient is pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Challenging Engagement on Cognition in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be adults at least 60 years old.~* At least 35 percent of participants will be men, and at least 15 percent will be minorities.~* 10th grade education or higher is required~* Fluent in English~* Alzheimer's Disease Assessment Scale-Cognitive (ADAS-COG) score of zero (a perfect score).~* A score of 18 or higher on the Barthel Index of Daily Functioning.~* Right-handed for magnetic resonance imaging (MRI) scanning.~Exclusion Criteria:~* Telephone Interview for Cognitive Status (TICS) lower than 25~* Montreal Cognitive Assessment (MOCA) score lower than 26~* Depression based on Center for Epidemiologic Studies Depression Scale (CESD) screening (a score of 27 or greater)~* Major psychiatric or neurological disorder~* Chemotherapy presently or in past year~* Coronary bypass presently or in past year~* History of major substance abuse~* History of central nervous system disease or brain injury~* Corrected vision poorer than 20/40 on Snellen Eye Chart after correction~* Recreational drug use in past six months~* Conditions which would contra-indicate MRI: Prior surgeries and/or implant of pacemakers, pacemaker wires, artificial heart valve, brain aneurysm surgery, middle ear implant, non-removable hearing aid or jewelry, braces or extensive dental work, cataract surgery or lens implant, implanted mechanical or electrical device, artificial limb or joint; foreign metallic objects in the body such as bullets, ball-bullets or ball bearings (BB's), shrapnel, or metalwork fragments; pregnancy, vertigo, claustrophobia, left handedness, Body Mass Index (BMI) greater than 35, uncontrollable shaking, or inability to lie still for one hour.~* More than minimal experience with photography during the last 12 years~* Work at a structured job/volunteer more than 10 hours per week~* Computer experience that involves more than internet surfing and email~* Use of electronic devices to shop, pay bills, bank, and perform other higher-order functions~* Extensive experience with digital photography or post processing photo programs

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- High-Demand Photography (Type: EXPERIMENTAL): A structured, high-demand photography course targeting 210 hours of engagement over 16 weeks.
- Moderate-Demand Photography (Type: ACTIVE_COMPARATOR): A structured, moderate-demand photography course targeting 210 hours of engagement over 16 weeks.
- At-Home Engagement Group (Type: PLACEBO_COMPARATOR): Participation, alone at home, in tasks that are relatively low in intellectual engagement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolism of Lipids in Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Low plasma phospholipids OR low plasma ratio of triglycerides to free fatty acids~* Recent weight loss~* Advanced stage lung cancer (Stage 3 or 4)~Exclusion Criteria:~* Having symptoms that may affect measures of fat metabolism (nausea, vomiting, problems swallowing, etc.)~* Taking n-3 fatty acid supplements such as fish oil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Metabolism (Type: None): Lung cancer patients who exhibit abnormalities in lipid measures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Malignant melanoma (including melanoma of unknown primary site, recurrent and pretreated systemic melanoma and/or melanoma with parenchymal CNS metastases) with leptomeningeal metastasis as demonstrated by a positive CSF (cerebrospinal liquor) cytology AND/OR by the presence of characteristic signs and symptoms of leptomeningeal metastasis supported by an MRI scan indicating the presence of meningeal tumour~* CSF flow abnormalities must be excluded~* Males or females ≥ 18 years of age~* Karnofsky Performance Status \> 50%~* Adequate organ function (adequate bone marrow reserve, adequate liver function, adequate renal function. adequate blood clotting)~Exclusion Criteria:~* Unresected parenchymal brain metastases with a diameter \> 3 cm~* Prior non melanoma malignancy (unless adequately treated carcinoma in situ of the cervix or non melanoma skin cancer)~* Prior intrathecal chemotherapy~* Prior treatment with systemic cytarabine or nitrosureas~* The patient ist pregnant or breast feeding~* Severe, active co-morbidities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prolonged Treatment for Infected Abortion After Hospital Discharge.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of intrauterine manipulation with contaminated objects.~* Vaginal secretion with fetid odor~* Presence of pus flowing through the cervical uterine~* Presence of peritonitis~* Leucocytosis (\> 14,000 leucocytes/mL)~* Vasodilatation, bounding pulse and paradoxically warm periphery with tachycardia (Heart rate\> 110 bpm)~* Cyanosis and/or paleness~* tachypnea(\> 30mpm)~* Arterial hypotension (SAP\< 90mmHg)~* Oliguria~* Fever (\> or = than 37,8°C)~Exclusion Criteria:~* Refusal to participate in the project~* Prior use of antibiotics within one week~* Known allergy to Doxycycline or Metronidazole~* Presence of tubo-ovarian abscess

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Use of antibiotics after hospital discharge
- 2 (Type: PLACEBO_COMPARATOR): Use of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed invasive cancer of the breast~* Patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.~* Patients must have HER2-positive breast cancer as defined by ASCO/CAP 2013 guidelines that is confirmed by a Sponsor-designated central laboratory~* Patients must have progressed on, or be intolerant to pertuzumab in the LABC/MBC setting or had disease recurrence within 12 months of pertuzumab treatment in the neoadjuvant or adjuvant setting.~* Patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the LABC/MBC setting~* Patients must have been previously treated with trastuzumab in any setting (which may have been previously administered with or without pertuzumab)~* ECOG Performance Status of 0 or 1~Exclusion Criteria:~* Patients who have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative~* Subjects with central nervous system (CNS) metastases, unless they have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment~* Patients with any class of New York Heart Association (NYHA) CHF or heart failure with preserved ejection fraction (HFPEF)~* Patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months~* Patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)~* Patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity~* Patients with a history of LVEF decline to below 50% during or after prior trastuzumab/lapatinib or other HER2 directed therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MM-302 + trastuzumab (Type: EXPERIMENTAL): MM-302 + trastuzumab
- Chemotherapy of Physician's Choice plus trastuzumab (Type: ACTIVE_COMPARATOR): Chemotherapy limited to one of the following: Gemcitabine, Capecitabine or Vinorelbine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Level of Accelerometer-assessed Preoperative Physical Activity and Short Term Outcome After Elective Cardiac Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult subject (≥ 60 years) awaiting elective cardiac surgery~* Patients affiliated or entitled to a social security scheme~* Patients who have received information about the study and have given their oral consent to participate~Exclusion Criteria:~* Pregnant woman,~* Major limitations in physical activity for orthopedic or musculoskeletal reasons~* Patients under judicial protection (curator or guardianship)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- complicated post-operative evolution (Type: None): Patients with a postoperative intensive care unity length of stay ≥ 5 days after elective cardiac surgery. They will have an accelerometer.
- simple post-operative evolution (Type: None): Patients with a postoperative intensive care unity length of stay \< 5 days after elective cardiac surgery. They will have an accelerometer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reletex for Nausea in GERD Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient over the age of 18 with clinically diagnosed GERD as evidenced by the GerdQ assessment tool and/or ambulatory pH/ pH- impedance monitoring with a component of nausea with or without vomiting.~* Continued symptoms despite a stable dose of FDA approved daily PPI therapy in addition to or without supportive anti-emetics. We will include patients with twice a day PPI dosing, as this is a standard treatment for PPI non-responders.~* Previous gastric emptying study performed as part of the standard care work-up of nausea and vomiting. Patients will be recruited regardless of the results and this information will only be used as a potential predictor for symptom response.~Exclusion Criteria:~* Currently participating in a concurrent clinical trial or completed another trial within past 8 weeks.~* Prior gastrointestinal surgery of the esophagus and stomach.~* Severe esophagitis (Los Angeles esophagitis Grade C and above), Barrett's metaplasia or eosinophilic esophagitis, achalasia or spastic motor disorder~* Unstable medical illness with ongoing diagnostic work-up and treatment. Patients with well-controlled hypertension, diabetes and a remote history of ischemic heart disease that is deemed stable, as judged by the physician-investigator can be included. Current drug or alcohol abuse or dependency.~* Current neurologic or cognitive illness or impairment which would make the patient an unsuitable candidate for hypnosis. This will be determined by the investigators before randomization using the Mini Mental Status Exam in patients with suspected impairment.~* Severe mental illness, e.g., uncontrolled major depression with suicidal ideation, active psychosis, diagnosis of schizophrenia-spectrum disorder.~* Those with nickel, gold, or other metal allergies.~* Those with other neuromodulators or implanted electrical devices such as cardiac pacemakers, AICD's, neurostimulators or transcutaneous electrical nerve stimulation devices (TENS units).~* Females who are or might become pregnant during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GERD subjects with nausea (Type: EXPERIMENTAL): subjects with GERD and nausea will receive treatment with Reletex

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* All patients must:~  * Have related donors who are identical at 6 human leukocyte antigens (HLA) loci (A, B and DR) by molecular typing~ * Have a performance status from 0-2~ * Give written informed consent~* Patients with sickle cell disease should have 1 or more of the following:~  * Acute chest syndrome requiring recurrent hospitalization or exchange transfusion~ * Nonhemorrhagic stroke or central nervous system event lasting longer than 24 hours~ * Recurrent vaso-occlusive pain (2 episodes or more per year) or recurrent priapism~ * Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30-50 percent of normal predicted value)~ * Bilateral proliferative retinopathy and major visual impairment in at least 1 eye~ * Osteonecrosis of multiple joints~* Patients with thalassemia should have 1 or more of the following:~  * Transfusion dependence, defined as a transfusion requirement of greater than or equal to 6 units of packed red blood cells over the past 12 months~ * Iron overload, defined as serum ferritin greater than 500 mcg/L in the absence of infection or biopsy-proven iron overload~ * Presence of 2 or more alloantibodies against red cell antigens~Exclusion criteria:~* Pregnancy~* Acute hepatitis (transaminases greater than 3 times the normal value)~* Cardiac ejection fraction less than 30 percent~* Severe renal impairment (glomerular filtration rate less than 30 percent of predicted normal value)~* Severe residual functional neurologic impairment (other than hemiplegia alone)~* Seropositivity for the human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allogeneic stem cell transplantation (Type: EXPERIMENTAL): Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Correlation Between Music Therapist's and Stroke Patient's Engagement Levels and Patient's Fingers and Wrist Movement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 55 and above.~2. Ability to understand and speak Hebrew.~3. First CVA (ischemic or hemorrhagic) with right side hemiparesis~4. Hand dominance: Right.~5. With sufficient autonomy in motor functions of upper limbs in order to use musical instruments.~6. Cognition: Mini-Mental State Examination \>24 or MoCA Test\>26.~7. No previous musical education.~Exclusion Criteria:~1. History of or current neurological or psychiatric disease.~2. Aphasia or amusia.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm study with two interventions (Type: OTHER): Single arm where each participant will undergo two interventions in the following order: Verbal Interaction and Music Therapeutic Interaction. Both interactions will be conducted by the same music therapist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* woman treated with anastrozole as adjuvant therapy for hormone-dependant breast cancer in post-menopausal women with positive hormone-receptors

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Strategy Training for People With Aphasia After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* primary diagnosis of acute stroke~* admission to acute rehabilitation~* mild to moderate aphasia but able to understand and express communication with verbal, written, and/or augmentative communication (score of 1 or 2 on the National Institutes of Health Stroke Scale item 9, or score 1 to 5 on the Boston Diagnostic Aphasia Examination Severity Scale)~Exclusion Criteria:~* pre-stroke diagnosis of dementia~* severe global aphasia (Boston Diagnostic Aphasia Examination Severity Scale score of 0)~* dysarthria as the only communication impairment (score of 1 or 2 two on the National Institutes of Health Stroke Scale item 10, but score of 0 on item 9)~* current major depressive disorder (unless treated and in partial remission), bipolar disorder, or any other psychotic disorder (indicated by PRIME-MD)severe global aphasia (Boston Diagnostic Aphasia Examination Severity Scale score of 0)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Strategy Training (Type: EXPERIMENTAL): Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility